Editorial
doi: 10.1080/14728222.2020.1709824.
Epub 2019 Dec 27.
RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer
Affiliations
- PMID: 31875730
- DOI: 10.1080/14728222.2020.1709824
Item in Clipboard
Editorial
RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer
Expert Opin Ther Targets.
2020 Jan.
No abstract available
Keywords: Kinase inhibitors; RSK2; targeted therapy; triple-negative breast cancer (TNBC).
Similar articles
-
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.Mol Cancer Ther. 2016 Nov;15(11):2598-2608. doi: 10.1158/1535-7163.MCT-16-0106. Epub 2016 Aug 15. Mol Cancer Ther. 2016. PMID: 27528706 Free PMC article.
-
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).Oncotarget. 2013 Feb;4(2):329-45. doi: 10.18632/oncotarget.834. Oncotarget. 2013. PMID: 23593654 Free PMC article.
-
Molecular Targeting of ERKs/RSK2 Signaling in Cancers.Curr Pharm Des. 2017 Nov 16;23(29):4247-4258. doi: 10.2174/1381612823666170714142338. Curr Pharm Des. 2017. PMID: 28714417 Review.
-
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.Stem Cells. 2012 Jul;30(7):1338-48. doi: 10.1002/stem.1128. Stem Cells. 2012. PMID: 22674792
-
Targeting RSK2 in human malignancies.Expert Opin Ther Targets. 2011 Jan;15(1):11-20. doi: 10.1517/14728222.2010.531013. Epub 2010 Oct 25. Expert Opin Ther Targets. 2011. PMID: 20969498 Review.
Cited by
-
Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy.Aging (Albany NY). 2024 Feb 14;16(4):3531-3553. doi: 10.18632/aging.205544. Epub 2024 Feb 14. Aging (Albany NY). 2024. PMID: 38358910 Free PMC article.
-
Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.Cancer Sci. 2023 Dec;114(12):4691-4705. doi: 10.1111/cas.15995. Epub 2023 Oct 15. Cancer Sci. 2023. PMID: 37840379 Free PMC article.
-
p90RSK2, a new MLCK mediates contractility in myosin light chain kinase null smooth muscle.Front Physiol. 2023 Sep 13;14:1228488. doi: 10.3389/fphys.2023.1228488. eCollection 2023. Front Physiol. 2023. PMID: 37781225 Free PMC article.
-
The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo.Cancers (Basel). 2023 Apr 8;15(8):2211. doi: 10.3390/cancers15082211. Cancers (Basel). 2023. PMID: 37190140 Free PMC article.
-
RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1.Front Pharmacol. 2022 Sep 20;13:950571. doi: 10.3389/fphar.2022.950571. eCollection 2022. Front Pharmacol. 2022. PMID: 36210843 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
